| 摘要: |
| 目的 探讨注射用重组人组织型纤溶酶原激酶衍生物致死性不良反应的特点和影响因素,为临床安全合理用药提供参考。方法 检索2012~2018年山东省药品不良反应数据库,筛选涉及怀疑用药为重组人组织型纤溶酶原激酶衍生物的死亡病例,进行统计、分析。结果 重组人组织型纤溶酶原激酶衍生物致死性不良反应主要表现为过敏反应和出血,与患者年龄、原患疾病、既往病史和合并用药均有关。结论 临床上要加强对重组人组织型纤溶酶原激酶衍生物致死性不良反应的认识,权衡利弊,准确把握溶栓治疗的指征和禁忌。 |
| 关键词: 重组人组织型纤溶酶原激酶衍生物 药品不良反应 死亡 分析 |
| DOI:10.13506/j.cnki.jpr.2018.10.017 |
| 基金项目: |
|
|
|
| Analysis of 9 cases of deaths coused by derivatives of Recombinant HumanTissue-type Plasminogen Activator for Injection |
| CUI Xiaokang,LU Changfei,XU Lili,LIU Wenwen,WU Shifu |
| (Shandong Center for Adverse Drug Reaction Monitoring,Jinan 250013,China) |
| Abstract: |
| Objective To explore the general characteristics of fatal adverse drug reactions (ADR) induced by derivatives of Recombinant HumanTissue-type Plasminogen Activator(rPA) for Injection in order to provide references and influence factor for rational and safe clinical drug use.Methods Fatal ADR cases induced by rPA in Shandong province database of adverse drug reactions during 2012~2018 were collected and analyzed statistically.Results The main performance of the fatal ADR of rPA were allergic reaction and bleeding, which were related to the age of patients, original disease,previous history and combined medication.Conclusion Fatal ADR of rPA should be strengthened in clinical.Medical staff should weigh the advantages and disadvantages before the use of rPA and grasp the indications and taboos of thrombolytic therapy accurately. |
| Key words: rPA Adverse drug reactions Fatal Analysis |